Contact:
PRISM BioLab Co., Ltd.
info@prismbiolab.com

26-1, Muraoka-Higashi 2chome. Fujisawa,Kanagawa 251-8555
www.prismbiolab.com

PRESS RELEASEPRISM BioLab, enters into a Joint Research and Licensing Agreementwith Ono
PRISM BioLab will utilize PepMetics®, innovative small molecules that mimic threedimensional structures of alpha-helix and beta-turns of peptides for drug discovery
against oncology target selected by Ono
TOKYO, Japan, 25 Apr 2024: -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development
biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets,today announced that it has entered into a target-exclusive research and licensing agreement with ONO
PHARMACEUTICAL CO., LTD. ("Ono ").
Under the terms of the agreement, Ono and PRISM will jointly create a development candidate for Ono’s
oncology target using PepMetics® technology. Upon identification of the development candidate, PRISM
will license its rights to Ono for clinical development and commercialization. The deal includes upfront
payments, pre-clinical, clinical and commercialization success-based milestones, royalties on future netsales, and other terms. Specific financial terms are not disclosed.
“We highly appreciate PRISM’s PepMetics® technology in PPI drug discovery”, said Seishi Katsumata,Executive Director, Discovery & Research of Ono. “Through this drug discovery collaboration, we areexcited to work with PRISM to identify and develop novel small molecule drugs for therapeutic targets that
had been previously difficult to modulate with a small molecule, leading to further expansion of ourdevelopment pipeline to address unmet medical needs across a broad range of diseases.”“We are very excited to enter into this collaboration with Ono who has a history of creating innovativedrugs. ”, said Dai Takehara, President & CEO of PRISM Biolab. “We believe that our PepMetics® technology
will change the current paradigm in drug discovery by turning previously undruggable PPIs into targets
readily druggable with small molecules. Through close collaboration between creative scientists of bothcompanies, we expect to generate innovative and game-changing drugs for the benefit of patients.”

About Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd., headquartered in Osaka, is an R&D-oriented pharmaceutical company
committed to creating innovative medicines in specific areas. ONO focuses its research on the oncology,immunology, neurology and specialty research with high medical needs as priority areas for discovery anddevelopment of innovative medicines. For further information, please visit the company’s website athttps://www.ono-pharma.com/.
About PRISM BioLab
PRISM BioLab is a discovery and development biotechnology company utilizing proprietary PepMetics®
technology to discover orally available small molecule inhibitors of protein-protein interaction (PPI) targets
and transform lives of patients suffering from cancer, autoimmune, fibrosis and other diseases. PepMetics®
are a unique class of small molecules that mimic three-dimensional structures of alpha-helix and beta-turn,the peptide structures commonly found in intracellular PPI interphases and receptor-ligand interactions. By
combining proprietary chemistry, know-how around PPI targets and AI-supported design, PepMetics®
technology can deliver inhibitors of challenging PPI targets. The technology holds promise to expand thefield of drug discovery by turning previously undruggable PPIs into targets readily druggable with small
molecules and by generating oral small molecule alternatives for injectable biologics.
PRISM BioLab is collaborating on new PPI targets with global and Japanese pharmaceutical companies.
PepMetics® targeting CBP/beta-catenin PPIs licensed to Eisai Co., Ltd. and Ohara Pharmaceuticals Co.,
Ltd. are in clinical development for cancer and liver disease, respectively.
www.prismbiolab.com